​In 2023 the GSK Immunisation Awards will be managed by the Public Health Association of Australia
(PHAA) as part of the Communicable Disease & Immunisation Conference (CDIC) to be held in Perth
from the 19 to 21 June 2023.

​

Four awards of AUD $20,000 each, will be awarded to support innovation programs of activity that clearly aim to meet one or more of the following criteria in either childhood, adolescent and/or adult vaccines:

​

• Improve access, coverage and/or timely delivery as per the Australian National Immunisation Program schedule.

• Improve access, coverage and/or timely delivery for hard-to-reach populations (including geographically distant populations, new Australian immigrants, refugees, asylum seekers).

• Utilise digital technology and/or social media to improve the Quality Use of Vaccines through innovation.

• Improve access, coverage and/or timely delivery for indigenous populations.

• Improve access, coverage and/or timely delivery for international travellers.
   

The projects submitted for entry should be innovative, and adaptable by other immunisation groups.

​

Important Dates

 

• Call for abstracts open - Thursday 12 January 2023

• Call for abstracts close - REVISED DATE: Wednesday 22 February 2023, 11:59pm AEDT

• Notification of abstract submissions - Friday 10 March 2023

• Finalist Applications open - Friday 10 March 2023

• Finalist Applications close - Sunday 2 April 2023, 11:59pm AEST

• Announcement of 2023 GSK Immunisation Awards - Tuesday 20 June 2023

​

AWARD APPLICATION PROCESS

​

​Phase 1 – Call for Abstracts - (Phase 1 Now Closed)

A Call for abstracts will take place for phase 1 of the Awards application process. Once the call for abstracts closes, submissions will be reviewed, and finalists notified. Finalists will then be asked to submit an application for the Award in phase 2.

​​​

Applications will be submitted using the appropriate Call for Abstracts Form.

​

Applicants must aim to meet one or more of the criteria. Each response should be no longer than 300 to 500 words.

 

Once the call for abstracts closes, submissions will be reviewed and finalists notified.

​

Finalised will then be asked to submit an application for the Awards in phase 2.

​

Phase 2 – Finalists' Applications  

 
Once finalists have been notified of their successful call for abstracts submission, they will be requested to submit the awards application.

​

The application must include a response to one or more of the criteria, as identified in the call for abstracts submission. Each response should be no more than 2,000 characters including spaces.

​

The application to be accompanied by at least one testimonial from a stakeholder, including examples of activities which have inspired the Application.

​

Applications will be submitted using the appropriate Application Form and be sent through with supporting documentation attached.

​

Awards winners will be notified at the Communicable Disease & Immunisation Conference Dinner on Tuesday 20 June 2023.

​

Recipient Benefits
 

The following benefits will be offered to Recipients of the GSK Immunisation Awards 2023:
 

• An award trophy, which is theirs to keep.

• An award certificate.

• A financial award of $20,000 to be used towards achieving innovation and best practice in childhood and adult immunisation.

• A travel awards of up to $3,000 to attend and present at the next Communicable Disease & Immunisation Conference in 2024.
   

Finalists
 

Finalists should use their best endeavours to attend or be represented at the Award Ceremony at the Communicable Diseases & Immunisation Conference. 

Finalists will be invited to attend the Dinner with up to 2 tickets per finalist application provided complementary.
 

Presentation

 

The awards will be presented during the Communicable Diseases & Immunisation Conference. The presentations will be made by the PHAA CEO and the sponsor of that award.

 

Monetary Award

​

Winners will receive an AUD $20,000 awards prize and a travel award of up to AUD $3,000 for attending the next Communicable Diseases & Immunisation Conference. The awards prize will be divided up into three allotted amounts for project reporting purposes of the awards.

​

Stage 1 – AUD $15,000 of the awards funding will be awarded following the announcement of the winners via direct deposit within three (3) business days following the announcement to the nominated organisation/representative of the awards project identified on the finalist application form.

​

Stage 2 - A following AUD $5,000 will be provided once the final awards project report is submitted no later than 5pm AEST on Friday 26 April 2024. If the project report is not received by 5pm AEST on Friday 26 April 2024, the remaining AUD $5,000 may be forfeited.

​

Stage 3 – Travel and registration will be awarded to the value of AUD $3,000 for attending and presenting at the next Communicable Disease & Immunisation Conference in 2024. A presentation and travel booking form will be sent to the GSK awards winners in February 2024 and to be returned by 5pm AEDT, 28 March 2024.

 

Reporting

​

Winners of the GSK Immunisation Awards will be required to submit a 1-year project report. A project report template will be provided and needs to be submitted no later than 5pm AEST on Friday 24 April 2024. On completion of the 1-year project report, the remaining AUD $5,000 of awards funding will be provided.

​

​

TERMS & CONDITIONS

​

Please view the full 2023 GSK Immunisation Awards terms and conditions by clicking the button below. 

​

​

​

 

APPLICATION FORM